Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomized, Open-Label Study of IMC-1121B With or Without Dacarbazine in Patients With Metastatic Malignant Melanoma

NCT00533702 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00533702
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00533702 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomized, Open-Label Study of IMC-1121B With or Without Dacarbazine in Patients With Metastatic Malignant Melanoma
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2007
Completion date
May 31, 2011
Enrollment
106 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic malignant melanoma